SecBot SecBot

TRAW

Traws Pharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001130598 Biotech & Drug Discovery
$0.3411 +0.00 (+0.32%)
Oct 26 4:00 PM ET · prev $0.3400
Market cap
$5.6M
Nano cap
Consensus
Sell
0% Buy or better · 7 analysts
Median target
$1.00
+193% · range $1.00–1.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.20
1 year
−86.9%
from $2.60 · Oct 27
30 days
−41.2%
from $0.5800
52-week range
$0.3400–2.82
−88% from high · low Oct 23
Avg volume 20D
176.2K
Oct 9 spike 687.2K
Short interest
🔒 Subscribers only
Insider net
+$998.2K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
23
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 4 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments, LLC, allowing…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $998.2K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 2 trimmed or exited.

  • AnalystsBEARISH

    0 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.630 → −$0.200 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    33% below its 50-day average. New closing low $0.3400 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED330,049$278.2K
JANE STREET GROUP, LLCDOUBLED216,006$182.2K
GEODE CAPITAL MANAGEMENT, LLCADD111,365$93.9K
VANGUARD FIDUCIARY TRUST COADD54,511$46.0K
MORGAN STANLEYNEAR_EXIT468$395.00
FMR LLCNEAR_EXIT2$2.00
GEODE CAPITAL MANAGEMENT, LLCADD77,103$141.1K
UBS Group AGTRIM4,053$7.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Sell 0% rate it Buy or better
Strong Buy0Buy0Hold4Sell1Strong Sell2
12-month targets · 1 analysts

Price is below the lowest target. Median implies +193%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 18, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral
Jun 18, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Jun 15, 2026Ladenburg Thalmann
DOWNGRADE
DOWNGRADENeutral
May 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$998.2K
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Jul 9, 2026
Savchuk Nikolay
Chief Operating Officer
AWARD93,000 sh
Jul 9, 2026
Dukes Iain D.
Chief Executive Officer
AWARD274,000 sh
Jul 9, 2026
Clarke Trafford
Director
AWARD14,150 sh
Jul 9, 2026
Shoemaker Mary Teresa
Director
AWARD14,150 sh
Jul 9, 2026
Leaman John Harold
Director
AWARD14,150 sh
Jul 9, 2026
Parker Charles Nolan
Chief Financial Officer
AWARD90,000 sh
Jul 9, 2026
Redfield Robert
Chief Medical Officer
AWARD84,000 sh
Jul 9, 2026
STOVER JACK E
Director
AWARD14,150 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.20
EPS estimate, this quarter
+68%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.20-$0.20–-$0.20+44.4%$0.00
Next Q-$0.29-$0.29–-$0.29+31.0%$0.00
Current FY-$1.33-$1.33–-$1.33+26.9%$0.00
Next FY-$1.88-$1.88–-$1.88+5.1%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 23, 2026 SEC
Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments, LLC, allowing the company…
8-K — Impact 7/10
Oct 20, 2026 SEC
Traws Pharma filed a DEFA14A (definitive additional proxy soliciting material) to provide a notice of internet…
DEFA14A — Impact 3/10
Aug 14, 2026 Earnings
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “
Jul 9, 2026 Insider
Savchuk Nikolay was granted 93,000 shares
Chief Operating Officer
Jul 9, 2026 Insider
Dukes Iain D. was granted 274,000 shares
Chief Executive Officer
Jul 9, 2026 Insider
Clarke Trafford was granted 14,150 shares
Director
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — DOUBLED
330,049 shares ($278.2K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
TRAW Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 14, 2026
Earnings
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage…
Aug 12, 2026
Earnings date
TRAW Q2 2026 Earnings Scheduled — 2026-08-12
Aug 5, 2026
Listing
Listing Status: TRAW — Deficient (was Normal)
Traws Pharma, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Jun 22, 2026
Regulatory
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of…
Jun 12, 2026
Press release
Traws Pharma Provides Regulatory Update on Influenza Program
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company…

SecBot reports

23 filings · 2 press releases · 1 bullish · 13 bearish · 2 mixed · 7 neutral
All TRAW filing & press-release reports (25)